Author

Sheena Sahota

Observed names: MD Sheena Sahota,, S Sahota, S. Sahota

Observed institutions: University of North Carolina at Chapel Hill, Rush University Medical Center, NewYork–Presbyterian Hospital, Cornell University, Neurology Associates, Weill Cornell Medicine, Rush University, University of Missouri–Kansas City, University of Missouri, University of Birmingham

OpenAlex ID: A5041935272

Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer

2021 · Jeremy Goc, Mengze Lv, et al. · Cell · 212

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer

2019 · Verena Sailer, Kenneth Wa Eng, et al. · JCO Precision Oncology · 42

Sacituzumab govitecan: an antibody–drug conjugate

2017 · Sheena Sahota, Linda T Vahdat · Expert Opinion on Biological Therapy · 35

Eight‐and‐a‐Half Syndrome

2009 · Aarti Sarwal, Mandeep Garewal, et al. · Journal of Neuroimaging · 25

Inpatient hemodialysis without anticoagulation in adults

2014 · S. Sahota, R. Rodby · Clinical Kidney Journal · 16

A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results.

2017 · Sheena Sahota, Naomi Kornhauser, et al. · Journal of Clinical Oncology · 12

TUB-030, a novel ADC targeting 5T4: A phase I/IIa multi-center, first-in-human clinical trial (5-STAR 1-01) in patients with advanced solid tumors.

2025 · Shiraj Sen, Sheena Sahota, et al. · Journal of Clinical Oncology · 3

Abstract CT154: BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study

2025 · Ecaterina E. Dumbrava, Ildefonso Ismael Rodriguez, et al. · Cancer Research · 1

Abstract P1-10-02: A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results

2018 · S Sahota, A Willis, et al. · Cancer Research · 1

Elevated serum creatinine in a patient with normal renal function: The value of C ystatin C

2015 · Sheena Sahota, Roger A Rodby, et al. · Nephrology · 1

A Phase 1 Study of a Mutant-selective Inhibitor, Cgt6297, in Patients With Advanced Solid Tumors Harboring Pik3ca Mutations

2026 · Dena Westphalen, Faisal Fa'Ak, et al. · International Journal of Gynecological Cancer

A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)–targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.

2026 · Manish R. Sharma, Jennifer Margaret Segar, et al. · Journal of Clinical Oncology

First-in-Human Study of a Novel Nonpeptide Drug Conjugate (CRN09682) in Patients With Somatostatin Receptor 2-Expressing Tumors

2026 · MD Daneng Li,, Al Hallak, MD, MS Mohammed Najeeb, et al. · Endocrine Abstracts

P3.18.88 Title:TUB-030, a Novel Adc: A Phase I/IIA Multi-Center, FIH Trial (5-STAR 1-01) in Patients With Advanced/Metastatic Solid Tumors

2025 · S. Sen, S. Sahota, et al. · Journal of Thoracic Oncology

Abstract A075: A protective role for group 3 innate lymphoid cells in colitis-associated colorectal cancer

2019 · Jeremy Goc, Nick Bessman, et al. · Cancer Immunology Research

Correlation of progression-free and overall survival with level of survivin, FoxP3, and OX40 in colorectal cancer patients treated with bevacizumab.

2011 · K. R. Shell, S. Sahota, et al. · Journal of Clinical Oncology

Favorable Outcome In Patients with Poor Prognosis Acute Myeloid Leukemia (AML) Using a 2-Day Induction Regimen Incorporating High Dose Cytarabine and Mitoxantrone.

2010 · Melissa L Larson, Sheena Sahota, et al. · Blood

Timed Sequential Induction Therapy with Cytarabine and Mitoxantrone In Acute Myeloid Leukemia (AML): A Well-Tolerated Regimen with High Response Rates In Older Patients and Transformed AML.

2010 · Sheena Sahota, Melissa L Larson, et al. · Blood

Works count: 18

Citation count: 348

H-index: 6

I10-index: 6